<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34728362</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-3441</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>169</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V</Title>
          <ISOAbbreviation>Eur J Pharm Biopharm</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Development of a novel beta-glucan supplemented hydrogel spray formulation and wound healing efficacy in a db/db diabetic mouse model.</ArticleTitle>
        <Pagination>
          <StartPage>280</StartPage>
          <EndPage>291</EndPage>
          <MedlinePgn>280-291</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejpb.2021.10.013</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0939-6411(21)00268-X</ELocationID>
        <Abstract>
          <AbstractText>To relieve the severe economic and social burdens and patient suffering caused by the increasing incidence of chronic wounds, more effective treatments are urgently needed. In this study, we focused on developing a novel sprayable wound dressing with the active ingredient β-1,3/1,6-glucan (βG). Since βG is already available as the active ingredient in a commercial wound healing product provided as a hydrogel in a tube (βG-Gel), the sprayable format should bring clinical benefit by being easily sprayed onto wounds; whilst retaining βG-Gel's physical stability, biological safety and wound healing efficacy. Potentially sprayable βG hydrogels were therefore formulated, based on an experimental design setup. One spray formulation, named βG-Spray, was selected for further investigation, as it showed favorable rheological and spraying properties. The βG-Spray was furthermore found to be stable at room temperature for more than a year, retaining its rheological properties and sprayability. The cytotoxicity of βG-Spray in keratinocytes in vitro, was shown to be promising even at the highest tested concentration of 100 μg/ml. The βG-Spray also displayed favorable fluid affinity characteristics, with a capacity to both donate and absorb close to 10% fluid relative to its own weight. Finally, the βG-Spray was proven comparably effective to the commercial product, βG-Gel, and superior to both the water and the carrier controls (NoβG-Spray), in terms of its ability to promote wound healing in healing-impaired animals. Contraction was found to be the main wound closure mechanism responsible for the improvement seen in the βG-treatment groups (βG-Spray and βG-Gel). In conclusion, the novel sprayable βG formulation, confirmed its potential to expand the clinical use of βG as wound dressing.</AbstractText>
          <CopyrightInformation>Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Grip</LastName>
            <ForeName>Jostein</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Biotec BetaGlucans AS, Tromsø 9019, Norway; Drug Transport and Delivery Research Group, Department of Pharmacy, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø 9037, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Steene</LastName>
            <ForeName>Erik</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Biotec BetaGlucans AS, Tromsø 9019, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Engstad</LastName>
            <ForeName>Rolf Einar</ForeName>
            <Initials>RE</Initials>
            <AffiliationInfo>
              <Affiliation>Biotec BetaGlucans AS, Tromsø 9019, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hart</LastName>
            <ForeName>Jeff</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Cica Biomedical Ltd, Knaresborough, North Yorkshire HG5 9AY, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bell</LastName>
            <ForeName>Andrea</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Cica Biomedical Ltd, Knaresborough, North Yorkshire HG5 9AY, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Skjæveland</LastName>
            <ForeName>Ingrid</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Biotec BetaGlucans AS, Tromsø 9019, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Basnet</LastName>
            <ForeName>Purusotam</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Women's Health and Perinatology Research Group, Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø 9037, Norway; Department of Obstetrics and Gynecology, University Hospital of North Norway, Sykehusveien, Tromsø 9038, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Škalko-Basnet</LastName>
            <ForeName>Nataša</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Drug Transport and Delivery Research Group, Department of Pharmacy, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø 9037, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Holsæter</LastName>
            <ForeName>Ann Mari</ForeName>
            <Initials>AM</Initials>
            <AffiliationInfo>
              <Affiliation>Drug Transport and Delivery Research Group, Department of Pharmacy, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø 9037, Norway. Electronic address: ann-mari.holsater@uit.no.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Eur J Pharm Biopharm</MedlineTA>
        <NlmUniqueID>9109778</NlmUniqueID>
        <ISSNLinking>0939-6411</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020100">Hydrogels</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047071">beta-Glucans</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>37361-00-5</RegistryNumber>
          <NameOfSubstance UI="C064197">beta-1,6-glucan</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9051-97-2</RegistryNumber>
          <NameOfSubstance UI="C033363">beta-1,3-glucan</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048909" MajorTopicYN="N">Diabetes Complications</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004339" MajorTopicYN="N">Drug Compounding</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004355" MajorTopicYN="N">Drug Stability</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020100" MajorTopicYN="N">Hydrogels</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008815" MajorTopicYN="N">Mice, Inbred Strains</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009779" MajorTopicYN="Y">Occlusive Dressings</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014945" MajorTopicYN="Y">Wound Healing</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014947" MajorTopicYN="Y">Wounds and Injuries</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047071" MajorTopicYN="N">beta-Glucans</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Beta-glucan</Keyword>
        <Keyword MajorTopicYN="N">Chronic wounds</Keyword>
        <Keyword MajorTopicYN="N">Hydrogel</Keyword>
        <Keyword MajorTopicYN="N">Spray formulation</Keyword>
        <Keyword MajorTopicYN="N">Wound dressing</Keyword>
        <Keyword MajorTopicYN="N">Wound healing</Keyword>
        <Keyword MajorTopicYN="N">db/db diabetic mice</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>3</Day>
          <Hour>5</Hour>
          <Minute>55</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34728362</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ejpb.2021.10.013</ArticleId>
        <ArticleId IdType="pii">S0939-6411(21)00268-X</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
